Cargando…
Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk?
BACKGROUND: Because of poor knowledge of risks and benefits, prophylactic explantation of high BIA-ALCL risk breast implant (BI) is not indicated. Several surgical risks have been associated with BI surgery, with mortality being the most frightening. Primary aim of this study is to assess mortality...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229447/ https://www.ncbi.nlm.nih.gov/pubmed/36376583 http://dx.doi.org/10.1007/s00266-022-03138-5 |
_version_ | 1785051256015814656 |
---|---|
author | Santanelli di Pompeo, Fabio Sorotos, Michail Clemens, Mark W. Paolini, Guido Anibaldi, Paolo Davoli, Marina Baglio, Giovanni Pinnarelli, Luigi Ferranti, Margherita Cerza, Francesco Cicala, Stefano Domenico Firmani, Guido |
author_facet | Santanelli di Pompeo, Fabio Sorotos, Michail Clemens, Mark W. Paolini, Guido Anibaldi, Paolo Davoli, Marina Baglio, Giovanni Pinnarelli, Luigi Ferranti, Margherita Cerza, Francesco Cicala, Stefano Domenico Firmani, Guido |
author_sort | Santanelli di Pompeo, Fabio |
collection | PubMed |
description | BACKGROUND: Because of poor knowledge of risks and benefits, prophylactic explantation of high BIA-ALCL risk breast implant (BI) is not indicated. Several surgical risks have been associated with BI surgery, with mortality being the most frightening. Primary aim of this study is to assess mortality rate in patients undergoing breast implant surgery for aesthetic or reconstructive indication. MATERIALS AND METHODS: In this retrospective observational cohort study, Breast Implant Surgery Mortality rate (BISM) was calculated as the perioperative mortality rate among 99,690 patients who underwent BI surgery for oncologic and non-oncologic indications. Mean age at first implant placement (A1P), implant lifespan (IL), and women’s life expectancy (WLE) were obtained from a literature review and population database. RESULTS: BISM rate was 0, and mean A1P was 34 years for breast augmentation, and 50 years for breast reconstruction. Regardless of indication, overall mean A1P can be presumed to be 39 years, while mean BIL was estimated as 9 years and WLE as 85 years. CONCLUSION: This study first showed that the BISM risk is 0. This information, and the knowledge that BI patients will undergo one or more revisional procedures if not explantation during their lifetime, may help surgeons in the decision-making process of a pre-emptive substitution or explant in patients at high risk of BIA-ALCL. Our recommendation is that patients with existing macrotextured implants do have a relative indication for explantation and total capsulectomy. The final decision should be shared between patient and surgeon following an evaluation of benefits, surgical risks and comorbidities. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266. |
format | Online Article Text |
id | pubmed-10229447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-102294472023-06-01 Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? Santanelli di Pompeo, Fabio Sorotos, Michail Clemens, Mark W. Paolini, Guido Anibaldi, Paolo Davoli, Marina Baglio, Giovanni Pinnarelli, Luigi Ferranti, Margherita Cerza, Francesco Cicala, Stefano Domenico Firmani, Guido Aesthetic Plast Surg Original Article BACKGROUND: Because of poor knowledge of risks and benefits, prophylactic explantation of high BIA-ALCL risk breast implant (BI) is not indicated. Several surgical risks have been associated with BI surgery, with mortality being the most frightening. Primary aim of this study is to assess mortality rate in patients undergoing breast implant surgery for aesthetic or reconstructive indication. MATERIALS AND METHODS: In this retrospective observational cohort study, Breast Implant Surgery Mortality rate (BISM) was calculated as the perioperative mortality rate among 99,690 patients who underwent BI surgery for oncologic and non-oncologic indications. Mean age at first implant placement (A1P), implant lifespan (IL), and women’s life expectancy (WLE) were obtained from a literature review and population database. RESULTS: BISM rate was 0, and mean A1P was 34 years for breast augmentation, and 50 years for breast reconstruction. Regardless of indication, overall mean A1P can be presumed to be 39 years, while mean BIL was estimated as 9 years and WLE as 85 years. CONCLUSION: This study first showed that the BISM risk is 0. This information, and the knowledge that BI patients will undergo one or more revisional procedures if not explantation during their lifetime, may help surgeons in the decision-making process of a pre-emptive substitution or explant in patients at high risk of BIA-ALCL. Our recommendation is that patients with existing macrotextured implants do have a relative indication for explantation and total capsulectomy. The final decision should be shared between patient and surgeon following an evaluation of benefits, surgical risks and comorbidities. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266. Springer US 2022-11-14 2023 /pmc/articles/PMC10229447/ /pubmed/36376583 http://dx.doi.org/10.1007/s00266-022-03138-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Santanelli di Pompeo, Fabio Sorotos, Michail Clemens, Mark W. Paolini, Guido Anibaldi, Paolo Davoli, Marina Baglio, Giovanni Pinnarelli, Luigi Ferranti, Margherita Cerza, Francesco Cicala, Stefano Domenico Firmani, Guido Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title | Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title_full | Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title_fullStr | Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title_full_unstemmed | Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title_short | Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk? |
title_sort | mortality rate in breast implant surgery: is an additional procedure worthwhile to mitigate bia-alcl risk? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229447/ https://www.ncbi.nlm.nih.gov/pubmed/36376583 http://dx.doi.org/10.1007/s00266-022-03138-5 |
work_keys_str_mv | AT santanellidipompeofabio mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT sorotosmichail mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT clemensmarkw mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT paoliniguido mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT anibaldipaolo mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT davolimarina mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT bagliogiovanni mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT pinnarelliluigi mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT ferrantimargherita mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT cerzafrancesco mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT cicalastefanodomenico mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk AT firmaniguido mortalityrateinbreastimplantsurgeryisanadditionalprocedureworthwhiletomitigatebiaalclrisk |